Drugdu.com expert's response:

Under the EU's In Vitro Diagnostic Regulation (IVDR), clinical performance studies must adhere to the following core standards to ensure the scientific validity, reliability, and compliance of the study results:

I. Regulatory Framework and Core Requirements

1. IVDR Regulation (Regulation (EU) 2017/746)

Clinical performance studies must comply with the requirements outlined in Articles 57-77 and Annex XIV of the IVDR, covering aspects such as study design, ethical review, subject protection, and data management.

It is necessary to demonstrate the scientific validity, analytical performance, and clinical performance of in vitro diagnostic reagents (IVDs), ensuring their association with specific clinical conditions or physiological states.

2. ISO 20916:2024 Standard

Core Role: As a harmonized standard under the IVDR, ISO 20916 provides a comprehensive framework for the planning, design, implementation, documentation, and reporting of clinical performance studies.

Key Content:

Presumption of Conformity: Compliance with the normative clauses of ISO 20916 is presumed to constitute compliance with the General Safety and Performance Requirements (GSPR) of the IVDR.

Risk Management: Emphasizes risks associated with specimen collection, data integrity, and alignment with IVDR risk management.

Ethical Requirements: Safeguards the rights, safety, dignity, and well-being of subjects, clarifying the ethical responsibilities of researchers, sponsors, and other parties.

Study Design: Includes inclusion/exclusion criteria, sample size calculation, and statistical analysis methods to ensure scientific rigor and minimize bias.

II. Study Design and Implementation Standards

1. Study Design

Clear Objectives: The study purpose must be clearly defined (e.g., evaluating diagnostic sensitivity, specificity, positive predictive value, etc.).

Control Group Setup: Appropriate control groups should be established based on the study type (e.g., interventional studies, retrospective studies).

Sample Size: The sample size should be determined according to the risk class and intended use (e.g., at least 1,000 cases for Class III IVDs and at least 200 cases for Class II IVDs).

2. Subject Protection

Ethical Review: Approval from an independent ethics committee is required to ensure compliance with ethical and moral standards.

Informed Consent: All subjects must sign an informed consent form that clearly outlines the study purpose, procedures, risks, and benefits.

Data Privacy: Compliance with the General Data Protection Regulation (GDPR) is mandatory to protect subjects' personal data and privacy.

3. Data Management and Analysis

Data Integrity: Subject data (e.g., baseline data, treatment outcomes, adverse reactions) must be accurately and completely collected and recorded.

Statistical Analysis: Scientific methods should be employed to analyze data and assess the safety, performance, accuracy, and reliability of IVDs.

Traceability: Ensure traceability of all data sources and processing procedures, with corresponding documentation provided.

III. Risk Management and Quality Control

1. Risk Management

Identify and control potential risks (e.g., risks associated with specimen collection, data bias) to ensure that residual risks are "as low as reasonably achievable."

Develop a Risk Management File (RMF), including risk analysis, risk control measures, and residual risk assessment.

2. Quality Control

Establish a Quality Management System (QMS) that complies with ISO 13485 standards, covering the entire process of study design, implementation, documentation, and reporting.

Utilize high-quality, standardized reagents and equipment, and conduct thorough validation and testing.

IV. Regulatory and Compliance Requirements

1. Involvement of Notified Bodies

High-risk IVDs (e.g., Class C and Class D) must undergo assessment by a notified body and obtain CE certification before they can be placed on the market.

The notified body's review includes technical documentation, the QMS, and the clinical performance study report.

2. Post-Market Surveillance (PMS)

Develop a PMS plan to continuously monitor product performance and safety, and regularly submit PMS reports or Periodic Safety Update Reports (PSURs).

For Class C and Class D IVDs, update the Performance Evaluation Report (PER) annually and conduct Post-Market Performance Follow-up (PMPF).

V. Special Scenarios and Additional Requirements

1. Interventional Studies

If study results may be used for treatment decisions, additional regulatory requirements under Article 58 of the IVDR must be met (e.g., stricter risk management and ethical review).

2. Companion Diagnostic Studies

IVDs involving companion diagnostics must clearly establish their association with specific drugs or treatment methods and comply with relevant regulatory requirements.

3. Studies Using Only Residual Samples

Specific conditions must be met (e.g., no additional burden on subjects), and notification or application to the competent authority may be required.